Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived

Subset Analysis in Clinical Studies Roundtable - March 11, 2020

https://www.niams.nih.gov/about/meetings-events/roundtables/subset-analysis-clinical-studies-roundtable-march-11-2020

This roundtable will be videocast on March 11, 2020. See draft agenda See participant list DRAFT Backgrounder Current State: Most clinical trials funded by NIAMS use traditional randomized clinical trial (RCT) designs, which measure the difference in average outcome between participants assigned to one intervention or another. However, it would be more clinically useful to understand who, within the relevant population, would likely benefit more from (or be harmed by) either intervention. This can be addressed to some extent in an RCT by stratification, but at a significant increase in costs and requiring pre-specification. Other strategies may also provide practical

Make a Donation

https://www.niams.nih.gov/about/budget/make-donation

Anyone, an individual or an organization, can donate to the NIAMS. The NIAMS is federally funded and not a fundraising organization; but, the U.S. Congress authorizes NIAMS to accept donations and bequests to support the scientific mission of the Institute. Donations to NIAMS are deposited in a NIAMS “Gift Fund”

Data and Safety Monitoring Boards—PI Responsibilities

https://www.niams.nih.gov/grants-funding/conducting-clinical-research/trial-policies-guidelines-templates/data-safety-monitoring-guidelines-policies/principal-investigator-responsibilities

The clinical study Principal Investigator (PI) safety monitoring responsibilities with respect to a Data and Safety Monitoring Board (DSMB) or Observational Study Monitoring Board (OSMB) ensure the study is conducted according to the highest scientific and ethical standards. Responsibilities are outlined in bold italics.

Osteoarthritis Initiative Application Guide for Biospecimen Studies

https://www.niams.nih.gov/grants-funding/funded-research/osteoarthritis-initiative/osteoarthritis-initiative-application

This document outlines the process by which requests for access to existing biospecimens from the OAI resource are processed, evaluated, and approved. Types of Specimen Available Type of Specimen Maximum Allowable Specimen Per Study Serum 0.15 ml (total of serum and plasma per study) EDTA plasma 0.15 ml (total of